CSL Overview

  • Year Founded
  • 1916

Year Founded

  • Status
  • Public

  • Employees
  • 32,000

Employees

  • Stock Symbol
  • CSL

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $187.64
  • (As of Tuesday Closing)

CSL General Information

Description

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Contact Information

Website
www.csl.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ASX
Corporate Office
  • 655 Elizabeth Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03) 0000 0000

CSL Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CSL Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$187.64 $185.88 $144.93 - $209.12 $90.3B 483M 653K $5.12

CSL Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022 FY 2021 30-Jun-2021
EV 107,239,181 101,285,180 88,379,872 101,519,725
Revenue 14,035,200 13,174,000 10,493,100 10,265,300
EBITDA 4,426,200 3,900,000 3,482,700 3,625,300
Net Income 2,471,800 2,194,000 2,254,700 2,375,000
Total Assets 37,304,000 36,234,000 28,346,000 18,156,900
Total Debt 12,107,000 12,227,000 9,657,800 5,806,900
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CSL Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CSL‘s full profile, request access.

Request a free trial

CSL Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived pro
Biotechnology
Melbourne, Australia
32,000 As of 2023
000.00
000000000 000.00

000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Gaithersburg, MD
0000 As of 0000
00000
000000000 00000

00000

em ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor inci
000000000000000
Basel, Switzerland
000000 As of 0000
000.00
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CSL Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novavax Corporation Gaithersburg, MD 0000 00000 000000000 00000
Roche Corporation Basel, Switzerland 000000 000.00 000000000000 000.00
Biocon Formerly PE-Backed Bengaluru, India 00000 000.00 00000000 000.00
Taibang Biological Group Private Equity-Backed Beijing, China 0000 00000 0000000 0000 00000
Novartis India Corporate Backed or Acquired Mumbai, India 00 00.000 0&0
You’re viewing 5 of 21 competitors. Get the full list »

CSL Patents

CSL Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024900957-A0 Protein formulations and uses thereof Inactive 05-Apr-2024
AU-2024900302-A0 Methods of delaying progression or hindering development of surgery-associated systemic inflammation Pending 09-Feb-2024
AU-2023903406-A0 Bioreactor for cell culture Pending 25-Oct-2023
AU-2023902975-A0 Soluble complement receptor type i variants and uses thereof Pending 15-Sep-2023
AU-2023902567-A0 Methods of treating metabolic disorders Pending 14-Aug-2023
To view CSL’s complete patent history, request access »

CSL Executive Team (8)

Name Title Board Seat Contact Info
Paul McKenzie Ph.D Chief Executive Officer, Chief Operating Officer & Managing Director
Joy Linton Chief Financial Officer
Mark Hil Chief Digital Information Officer
Bill Campbell Executive Vice President & Chief Commercial Officer
Jeffrey Ball Chief Sustainability Officer & Senior Vice President
You’re viewing 5 of 8 executive team members. Get the full list »

CSL Board Members (15)

Name Representing Role Since
000000 0000000 Self Board Member 000 0000
000000 00000000000 Self Board Member 000 0000
00000 0000000 CSL Chairman & Board Member 000 0000
00000 00000 CSL Board Member 000 0000
0000000 000000 CSL Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

CSL Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CSL Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CSL‘s full profile, request access.

Request a free trial

CSL Investments & Acquisitions (9)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CSL Vifor 09-Aug-2022 0000000000 000.00 Pharmaceuticals 0000 0000
Ena Respiratory 15-Jun-2021 00000 0000 000.00 Drug Discovery
Denteric 26-Sep-2019 00000 0000 000.00 Drug Discovery
Calimmune 28-Aug-2017 0000000000 00000 Biotechnology 0000 0000
Wuhan Zhong Yuan Rui De Biological Products 03-Aug-2017 Merger/Acquisition 00000 Drug Discovery 0000 0000
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

CSL Subsidiaries (3)

Company Name Industry Location Founded
CSL Plasma Acquirer 2019
CSL Vifor Pharmaceuticals Glattbrugg, Switzerland 0000
Seqirus Other Pharmaceuticals and Biotechnology Holly Springs, NC 0000
To view CSL’s complete subsidiaries history, request access »

CSL ESG

Risk Overview

Risk Rating

Updated May, 01, 2024

24.87 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 407

Rank

00.00

Percentile

To view CSL’s complete esg history, request access »

CSL Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Environmental Support Solutions 09-Apr-2006 00000 00000 00 000 Completed
  • 3 buyers
To view CSL’s complete exits history, request access »

CSL FAQs

  • When was CSL founded?

    CSL was founded in 1916.

  • Who is the CEO of CSL?

    Paul McKenzie Ph.D is the CEO of CSL.

  • Where is CSL headquartered?

    CSL is headquartered in Melbourne, Australia.

  • What is the size of CSL?

    CSL has 32,000 total employees.

  • What industry is CSL in?

    CSL’s primary industry is Biotechnology.

  • Is CSL a private or public company?

    CSL is a Public company.

  • What is CSL’s stock symbol?

    The ticker symbol for CSL is CSL.

  • What is the current stock price of CSL?

    As of 28-May-2024 the stock price of CSL is $187.64.

  • What is the current market cap of CSL?

    The current market capitalization of CSL is $90.3B.

  • What is CSL’s current revenue?

    The trailing twelve month revenue for CSL is $14B.

  • Who are CSL’s competitors?

    Novavax, Roche, Biocon, Taibang Biological Group, and Novartis India are some of the 21 competitors of CSL.

  • What is CSL’s annual earnings per share (EPS)?

    CSL’s EPS for 12 months was $5.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »